Iva Annua Pollen

Dosage for Iva Annua Pollen is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity level (determined via skin testing) and clinical history. There is no 'standard' dose for all patients.

Immunotherapy Phases

1. 1Build-up (Escalation) Phase: This phase typically lasts 3 to 6 months. It begins with a very low concentration (e.g., 0.05 mL of a 1:100,000 w/v dilution). Injections are usually given 1 to 3 times per week. The dose is gradually increased until the 'maintenance dose' is reached.
2. 2Maintenance Phase: Once the effective dose is reached, the frequency of injections is reduced to once every 2 to 4 weeks. This phase generally continues for 3 to 5 years to ensure long-term desensitization.

Standard maintenance doses often range from 0.2 mL to 0.5 mL of a 1:100 w/v or 1:20 w/v concentration, depending on the manufacturer and patient tolerance.

Iva Annua Pollen is generally considered safe for use in children, typically starting at age 5. Younger children may receive immunotherapy if the clinician determines the benefit outweighs the risk and the child can cooperate with the injection schedule and observation period. The dosing schedule for children is similar to adults but may involve more cautious increments during the build-up phase.

Renal Impairment

No specific dosage adjustments are provided for renal impairment, as the systemic protein load is minimal. However, patients with severe renal disease may have altered fluid balance or cardiovascular stability, which could complicate the management of a systemic reaction.

Hepatic Impairment

No adjustments are required for hepatic impairment. The metabolism of allergenic proteins does not rely on the cytochrome P450 system.

Elderly Patients

Elderly patients (over 65) require careful evaluation. While age itself is not a contraindication, the presence of underlying cardiovascular disease or the use of beta-blockers (which are common in this age group) may increase the risk and severity of adverse reactions to the extract.

Iva Annua Pollen extracts are NOT for self-administration. They must be administered by a healthcare professional in a clinical setting equipped to handle emergencies.

• Route: Subcutaneous injection (SCID), usually in the posterior aspect of the upper arm.
• Observation: Patients MUST remain in the clinic for at least 30 minutes following every injection to monitor for signs of anaphylaxis.
• Storage: Extracts should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should never be frozen, as freezing can denature the allergenic proteins.
• Site Rotation: Injection sites should be rotated between arms to minimize local tissue reactions.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If a dose is missed during the maintenance phase by more than a week, the physician may reduce the dose for the next injection to ensure safety. Never 'double up' on doses to catch up.

An 'overdose' in the context of allergenic extracts usually refers to the administration of a dose higher than the patient's current tolerance level, which can trigger a systemic allergic reaction or anaphylaxis.

Signs of Overdose/Systemic Reaction:

• Generalized hives (urticaria)
• Swelling of the throat or tongue
• Wheezing or difficulty breathing
• Rapid drop in blood pressure (hypotension)
• Fainting or dizziness

Emergency Measures:

Immediate administration of epinephrine (1:1000) is the primary treatment for an immunotherapy overdose. Supportive care with oxygen, intravenous fluids, and antihistamines may follow.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Always report any illness or new medications to your allergist before receiving your injection.

Most patients receiving Iva Annua Pollen immunotherapy will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Swelling (Wheal): A raised, red bump at the site of injection. This typically appears within minutes and may last for several hours.
• Redness (Erythema): Reddening of the skin around the injection site, which may feel warm to the touch.
• Itching (Pruritus): Localized itching at the injection site is very common.
• Tenderness: The arm may feel slightly sore or heavy for 24 hours following the injection.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter. These may peak 6-12 hours after the injection and can persist for 2-3 days.
• Fatigue: Some patients report feeling unusually tired for a few hours after their 'allergy shot.'
• Mild Nasal Congestion: A slight increase in hay fever symptoms shortly after administration.

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Gastrointestinal Distress: Nausea, abdominal cramping, or diarrhea shortly after an injection.

> Warning: Stop taking Iva Annua Pollen and call your doctor immediately if you experience any of these symptoms of a systemic reaction or anaphylaxis.

• Upper Airway Obstruction: Feeling of 'throat closing,' hoarseness, or difficulty swallowing.
• Lower Airway Obstruction: Severe wheezing, chest tightness, or shortness of breath (bronchospasm).
• Cardiovascular Collapse: Dizziness, lightheadedness, rapid or weak pulse, and fainting, indicating a dangerous drop in blood pressure.
• Cyanosis: Bluish tint to the lips or fingernails, indicating a lack of oxygen.
• Uterine Contractions: In pregnant women, systemic reactions can potentially trigger uterine activity.

There are no known long-term 'toxic' side effects associated with the prolonged use of Iva Annua Pollen extracts. The primary long-term effect is the desired modulation of the immune system. However, patients should be monitored for 'late-phase' reactions that can occur 6-24 hours after an injection, although these are rarely dangerous if the initial 30-minute period was stable.

Allergenic extracts, including Iva Annua Pollen, carry a class-wide FDA warning regarding the risk of severe systemic reactions.

Summary of Warning:

• Anaphylaxis Risk: This product can cause severe, life-threatening systemic reactions, including anaphylaxis.
• Supervision: It must only be administered in a setting where emergency equipment and personnel trained in treating anaphylaxis are immediately available.
• Patient Status: Patients with unstable or severe asthma are at a higher risk for fatal reactions and should be evaluated carefully before each dose.
• Pre-existing Conditions: Certain medications, such as beta-blockers, may make a patient non-responsive to the usual doses of epinephrine used to treat a reaction.

Report any unusual symptoms to your healthcare provider. Even a large local reaction should be reported, as it may be a sign that the next dose needs to be adjusted to prevent a systemic reaction.

Iva Annua Pollen is a potent biological agent. Its safety depends heavily on proper administration and patient screening. Patients must be 'clinically stable' before receiving an injection. This means they should not be experiencing an acute asthma flare-up or a significant increase in their baseline allergy symptoms on the day of the injection.

No FDA black box warnings for Iva Annua Pollen specifically, but it falls under the general warning for all allergenic extracts regarding Anaphylaxis. The label warns that these products can cause severe systemic reactions which may result in death. Patients must be observed for at least 30 minutes post-injection.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. The risk is highest during the build-up phase or when switching to a new vial of extract (even if it is the same concentration).
• Asthma Status: Patients with uncontrolled or severe asthma (FEV1 < 70% of predicted) are at the highest risk for a fatal reaction to immunotherapy. Injections should be withheld if the patient is wheezing or using their rescue inhaler more frequently than usual.
• Beta-Blocker Use: Patients taking beta-blockers (used for heart conditions or migraines) may be resistant to the effects of epinephrine, the standard treatment for anaphylaxis. This is a significant safety concern.
• Acute Illness: If a patient has a fever or a respiratory infection, the injection should be postponed until they have recovered.

Unlike many drugs, Iva Annua Pollen does not require routine blood counts or liver function tests. Instead, monitoring is clinical:

• Pre-Injection Screening: The healthcare provider will ask about any reactions to the previous dose and check for current asthma symptoms.
• Post-Injection Observation: A mandatory 30-minute wait time in the office is required.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before the injection to ensure lung function is stable.

Generally, Iva Annua Pollen does not cause drowsiness or impairment. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until cleared by a physician.

There is no direct chemical interaction between alcohol and Iva Annua Pollen. However, alcohol consumption can cause vasodilation (widening of blood vessels), which might theoretically increase the rate of allergen absorption or worsen the symptoms of an allergic reaction. It is generally advised to avoid alcohol for several hours after an injection.

Immunotherapy is typically discontinued after 3 to 5 years of successful maintenance. There is no 'withdrawal syndrome' associated with stopping Iva Annua Pollen. However, if therapy is stopped prematurely, the patient's allergy symptoms are likely to return over time. If a patient experiences a life-threatening reaction, therapy may be permanently discontinued.

> Important: Discuss all your medical conditions with your healthcare provider before starting Iva Annua Pollen. Ensure they are aware of all medications you are taking, especially those for blood pressure or heart rhythm.

While there are few absolute contraindications, the following combinations are generally avoided due to extreme risk:

• Beta-Blockers (Non-selective and Selective): Drugs like propranolol, atenolol, or metoprolol. Clinical Consequence: In the event of anaphylaxis, beta-blockers prevent epinephrine from working effectively, which can lead to death. Management: Patients should ideally be switched to an alternative class of medication (like ACE inhibitors or CCBs) before starting immunotherapy.

• ACE Inhibitors: Drugs like lisinopril or enalapril. Mechanism: ACE inhibitors interfere with the body's ability to break down bradykinin, a substance involved in allergic swelling. Clinical Consequence: May increase the risk or severity of systemic reactions. Management: Use with extreme caution and monitor the patient closely.
• MAO Inhibitors: Drugs like phenelzine or selegiline. Clinical Consequence: These can potentiate the effect of epinephrine if it is needed for an emergency, leading to a hypertensive crisis.

• Antihistamines: While often used to manage symptoms, antihistamines (like loratadine or cetirizine) can mask the early warning signs of a systemic reaction (like itching or hives). This could delay the diagnosis of a worsening reaction. Management: Patients are often told to remain on a consistent dose of antihistamines rather than taking them sporadically.
• Other Allergenic Extracts: If a patient is receiving multiple types of immunotherapy (e.g., for dust mites and Iva Annua), the cumulative allergen load increases the risk of a systemic reaction.

There are no known direct food interactions with Iva Annua Pollen. However, patients with a 'pollen-food allergy syndrome' (Oral Allergy Syndrome) may experience cross-reactivity. For example, some people allergic to weeds in the Asteraceae family may react to foods like melon, banana, or chamomile tea. This is not an interaction with the drug itself but a related allergic phenomenon.

• St. John's Wort: No direct interaction, but it can affect the metabolism of other medications the patient might be taking for asthma.
• Echinacea: Some immunologists suggest avoiding immune-stimulating herbs during immunotherapy, although clinical data is lacking.

• Skin Tests: Iva Annua Pollen will obviously interfere with future skin tests for the same allergen.
• Total IgE and Specific IgE: Immunotherapy will cause changes in these lab values. Initially, specific IgE may rise, followed by a long-term decline. Specific IgG4 levels will typically rise significantly. These are expected therapeutic changes rather than 'interference.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even over-the-counter cold medicines can affect how your body responds to immunotherapy.

Iva Annua Pollen must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients with a baseline FEV1 of less than 70% of predicted or those who have had a recent life-threatening asthma exacerbation. Mechanism: These patients have no pulmonary reserve; a systemic allergic reaction causing further bronchospasm is likely to be fatal.
2. 2Recent Myocardial Infarction or Unstable Angina: Mechanism: The heart may not be able to tolerate the stress of a systemic reaction or the high doses of epinephrine required to treat it.
3. 3Hypersensitivity to Excipients: Patients known to be allergic to glycerin or phenol (used as a preservative in the extract).

These conditions require a careful risk-benefit analysis by the physician:

• Beta-Blocker Therapy: As mentioned, this makes treating anaphylaxis difficult. If the patient cannot be switched to another medication, immunotherapy may be deemed too risky.
• Autoimmune Disorders: There is a theoretical risk that stimulating the immune system could worsen conditions like lupus or rheumatoid arthritis, though evidence is limited.
• Malignancy: Patients with active cancer are generally not started on immunotherapy, as their immune system is already compromised or under stress.
• Severe Atopic Dermatitis: While not a contraindication, these patients may have more difficulty with local reactions.

Patients allergic to Iva Annua Pollen often show cross-sensitivity to other members of the Asteraceae family, including:

• Ragweed (*Ambrosia* species)
• Chrysanthemums
• Marigolds
• Dandelions

If a patient has had a severe reaction to any of these pollens, the starting dose for Iva Annua Pollen should be exceptionally low.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Iva Annua Pollen. A thorough physical exam and review of your current medications are essential for safety.

FDA Pregnancy Category C.

There are no adequate and well-controlled studies of Iva Annua Pollen in pregnant women. However, clinical guidelines generally suggest:

• Maintenance: If a woman is already on a stable maintenance dose and becomes pregnant, the therapy is usually continued, as the risk of a systemic reaction is low.
• Initiation: Immunotherapy is almost NEVER started during pregnancy. The risk of a systemic reaction (anaphylaxis) during the build-up phase poses a significant threat to the fetus, potentially causing uterine contractions and fetal hypoxia (lack of oxygen).

It is not known whether the components of Iva Annua Pollen extract are excreted in human milk. However, because these are large proteins that are digested in the infant's gut, the risk to a nursing infant is considered negligible. Breastfeeding is not a contraindication for continuing immunotherapy.

Iva Annua Pollen is approved for use in children. Clinical studies have shown that allergen immunotherapy can not only reduce symptoms in children but may also prevent the development of new sensitivities and reduce the risk of progressing from allergic rhinitis to asthma (the 'allergic march'). Children should be at least 5 years old to ensure they can communicate symptoms of a reaction and tolerate the injection procedure.

In patients over 65, the decision to use Iva Annua Pollen must be made with caution. Older adults are more likely to have cardiovascular disease, which increases the risk of complications from anaphylaxis. Additionally, they are more likely to be taking medications like beta-blockers or ACE inhibitors that complicate the safety profile.

There is no evidence that renal impairment affects the safety or efficacy of Iva Annua Pollen. Because the drug is a biological protein administered in minute quantities, it does not accumulate in the body like traditional drugs. No GFR-based adjustments are necessary.

Liver disease does not affect the metabolism of allergenic extracts. No dosage adjustments are required for patients with hepatic impairment. However, if the patient has severe systemic illness due to liver failure, immunotherapy may be postponed.

> Important: Special populations require individualized medical assessment. Pregnant women or those planning to become pregnant should discuss their immunotherapy schedule with both their allergist and their obstetrician.

Iva Annua Pollen extract acts as an immunomodulator. Its primary molecular target is the adaptive immune system, specifically the balance between T-helper type 2 (Th2) cells and T-helper type 1 (Th1) / Regulatory T (Treg) cells.

In an allergic state, Th2 cells produce cytokines like IL-4 and IL-13, which signal B-cells to produce IgE. By introducing the Iva annua proteins subcutaneously in increasing amounts, the extract induces 'high-zone tolerance.' This leads to the expansion of Treg cells that produce IL-10. IL-10 is a critical cytokine that suppresses IgE production and instead promotes the production of IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody, binding to the pollen proteins before they can reach the IgE on mast cells.

• Dose-Response: There is a clear dose-response relationship in immunotherapy. Higher maintenance doses are generally more effective than lower doses, but they also carry a higher risk of systemic reactions.
• Onset of Effect: The clinical effect is not immediate. It typically takes 3 to 6 months (reaching the maintenance phase) before patients notice a reduction in symptoms.
• Duration: The effects are long-lasting. Studies on similar pollen extracts suggest that after 3-5 years of treatment, the benefits can persist for several years after the injections are stopped.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous administration) |

| Protein Binding | Minimal (interacts with antibodies) |

| Half-life | Minutes to hours (proteins) |

| Tmax | 1-2 hours (systemic absorption) |

| Metabolism | Proteolysis (proteases/peptidases) |

| Excretion | Renal (as peptide fragments) |

• Molecular Formula: Complex mixture of proteins, glycoproteins, and polysaccharides.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for major allergens.
• Solubility: Highly soluble in aqueous buffers and saline.
• Structure: The extract contains numerous proteins, but the most clinically relevant are the 'major allergens'—specific proteins that bind IgE in more than 50% of sensitive patients.

Iva Annua Pollen is a Non-Standardized Pollen Allergenic Extract. It is part of the therapeutic class of Biologicals, specifically used for 'Specific Immunotherapy' (SIT). It is related to other weed pollen extracts like Short Ragweed (Ambrosia artemisiifolia) and Cocklebur (Xanthium commune).